Effect of New Antiviral Agent Camphecin on Behavior of Mice

Babina, A. V.; Лавриненко, В. А.; Yarovaya, Оlga I.; Salakhutdinov, N. F.

doi:10.1007/s10517-017-3612-6

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We studied metabolism of the xenobiotic and found out the distribution of the substance in animal organs [29]. We showed safety and absence of side effect on animals' CNS in the open field test [30]. We studied the mechanism of action of the new antiviral agent, proved that camphecene binds to hemagglutinin of influenza virus, and found out what amino acid substitutions appear when resistance to camphecene develops [31].…”

Section: Introductionmentioning

confidence: 99%

Optimization of application schedule of camphecene, a novel anti‐influenza compound, based on its pharmacokinetic characteristics

Zarubaev

Гаршинина

Volobueva

et al. 2022

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Due to high variability and rapid life cycle, influenza virus is able to develop drug resistance against direct‐acting antivirals. Development of novel virus‐in113039hibiting drugs is therefore important goal. Previously, we identified camphor derivative, camphecene, as an effective anti‐influenza compound. In the present study, we optimize the regimen of its application to avoid high sub‐toxic concentrations. The protective activity of camphecene was assessed on the model of lethal pneumonia of mice caused by influenza viruses. Camphecene was administered either once a day or four times a day, alone or in combination with Tamiflu. Mortality and viral titer in the lungs were studied. Pharmacokinetics of camphecene was studied in rabbits. We have demonstrated that camphecene, being used every 6 h at a dose of 7.5 mg/kg/day, results in antiviral effect that was statistically equal to the effect of 100 mg/kg/day once a day, that is, the same effect was achieved by 13 times lower daily dose of the drug. This effect was manifested in decrease of mortality and decrease of virus' titer in the lungs. The studies of pharmacokinetics of camphecene have demonstrated that it does not accumulate in blood plasma and that its m ultiple applications with dosage interval of 65 min are safe. In addition, the results of the study demonstrate also that camphecene possesses additive effect with Tamiflu, allowing to decrease the dose of the latter. The results suggest that due to safety and efficacy, camphecene can be further developed as potential anti‐influenza remedy.

show abstract

Section: Introductionmentioning

confidence: 99%